The US Food and Drug Administration (FDA) today announced that it has granted accelerated approval for Merck’s anti-PD-1 agent pembrolizumab (Keytruda) for treating patients with refractory metastatic non-small cell lung cancer (NSCLC) tumors that express programmed cell death protein ligand 1 (PD-L1).
The US Food and Drug Administration (FDA) has approved nivolumab (Opdivo) in combination with ipilimumab (Yervoy) for treating patients with BRAF V600 wild-type unresectable or metastatic melanoma.
A high number of patient life-years are lost to regulatory delays for drug approvals, according to an analysis presented at the 2015 World Conference on Lung Cancer.
Seventy-five percent of patients diagnosed with metastatic adenocarcinoma of the lung before age 40 have an actionable mutation, according to preliminary results from the Genomics of Young Lung Cancer Study.
Patients with stage IV squamous cell lung cancer positive for an EGFR gene copy number biomarker saw a survival benefit when adding cetuximab to chemotherapy.
The newly revised 8th edition of the tumor, node, and metastasis (TNM) classification of lung cancer will improve the precision of staging and provide physicians with new data with which to treat patients.
The incidence of NSCLC among self-reported never-smokers appears to be increasing, according to authors of two retrospective studies presented at the 2015 World Conference on Lung Cancer.
The investigational agent IMMU-32 is well-tolerated in patients with previously-treated metastatic lung cancer, and interim survival data are “encouraging.”
Oncology teams need to spot emerging immune-related adverse events associated with immunotherapies early in order to avoid treatment discontinuation.
Treatment with nivolumab and ipilimumab is clinically active and has a manageable safety profile for chemotherapy-naive patients diagnosed with advanced NSCLC.